Nordic Pharma Announces European Launch of Lacrifill® Canalicular Gel
-
By
February 10, 2026
-
2 min
Nordic Pharma has launched Lacrifill®, a new therapy for dry eye, in Europe following its CE mark approval in 2025. This innovative cross-linked hyaluronic acid gel temporarily occludes the tear drainage system, enhancing tear film preservation and providing long-lasting relief for up to six months. Dry eye affects up to 30% of Europeans and poses challenges for patients undergoing surgeries like cataract or LASIK, potentially compromising outcomes. Experts believe Lacrifill® will improve ocular surface health before and after surgical procedures.
1. Lacrifill® launched in Europe in 2025. 2. It is a cross-linked hyaluronic acid gel. 3. Temporarily blocks tear drainage. 4. Provides relief for up to six months. 5. Affects 30% of the European population. 6. Important for cataract and LASIK surgery candidates. 7. Aims to optimize ocular surface health. 8. Supported by leading ophthalmology experts.
Listen Tab content
